Immunterapi mod Alzheimers sygdom

Alexander Christian Falkentoft; Steen Gregers Hasselbalch

Immunterapi mod Alzheimers sygdom

Translated title of the contribution: Immunotherapy for Alzheimer's disease

Alexander Christian Falkentoft, Steen Gregers Hasselbalch

Department of Clinical Medicine

1 Citation (Scopus)

Abstract

Passive anti-beta-amyloid (Aß) immunotherapy has been shown to clear brain Aß deposits. Results from phase III clinical trials in mild-to-moderate Alzheimer's disease (AD) patients with two monoclonal antibodies bapineuzumab and solanezumab and intravenous immunoglobulin have been disappointing. Subsequent analysis of pooled data from both phase III trials with solanezumab showed a reduction in cognitive decline in patients with mild AD. Solanezumab and new monoclonal antibodies are being tested in patients with prodromal and preclinical AD in search for a disease-modifying treatment.

Translated title of the contribution	Immunotherapy for Alzheimer's disease
Original language	Danish
Journal	Ugeskrift for Laeger
Volume	178
Issue number	3
Pages (from-to)	2-6
Number of pages	5
ISSN	0041-5782
Publication status	Published - 18 Jan 2016

Keywords

English Abstract
Journal Article

Cite this

@article{b2624c49307c4ca2bd5385c44130e58f,

title = "Immunterapi mod Alzheimers sygdom",

abstract = "Passive anti-beta-amyloid (A{\ss}) immunotherapy has been shown to clear brain A{\ss} deposits. Results from phase III clinical trials in mild-to-moderate Alzheimer's disease (AD) patients with two monoclonal antibodies bapineuzumab and solanezumab and intravenous immunoglobulin have been disappointing. Subsequent analysis of pooled data from both phase III trials with solanezumab showed a reduction in cognitive decline in patients with mild AD. Solanezumab and new monoclonal antibodies are being tested in patients with prodromal and preclinical AD in search for a disease-modifying treatment.",

keywords = "English Abstract, Journal Article",

author = "Falkentoft, {Alexander Christian} and Hasselbalch, {Steen Gregers}",

year = "2016",

month = jan,

day = "18",

language = "Dansk",

volume = "178",

pages = "2--6",

journal = "Ugeskrift for Laeger",

issn = "0041-5782",

publisher = "Almindelige Danske Laegeforening",

number = "3",

}

TY - JOUR

T1 - Immunterapi mod Alzheimers sygdom

AU - Falkentoft, Alexander Christian

AU - Hasselbalch, Steen Gregers

PY - 2016/1/18

Y1 - 2016/1/18

N2 - Passive anti-beta-amyloid (Aß) immunotherapy has been shown to clear brain Aß deposits. Results from phase III clinical trials in mild-to-moderate Alzheimer's disease (AD) patients with two monoclonal antibodies bapineuzumab and solanezumab and intravenous immunoglobulin have been disappointing. Subsequent analysis of pooled data from both phase III trials with solanezumab showed a reduction in cognitive decline in patients with mild AD. Solanezumab and new monoclonal antibodies are being tested in patients with prodromal and preclinical AD in search for a disease-modifying treatment.

AB - Passive anti-beta-amyloid (Aß) immunotherapy has been shown to clear brain Aß deposits. Results from phase III clinical trials in mild-to-moderate Alzheimer's disease (AD) patients with two monoclonal antibodies bapineuzumab and solanezumab and intravenous immunoglobulin have been disappointing. Subsequent analysis of pooled data from both phase III trials with solanezumab showed a reduction in cognitive decline in patients with mild AD. Solanezumab and new monoclonal antibodies are being tested in patients with prodromal and preclinical AD in search for a disease-modifying treatment.

KW - English Abstract

KW - Journal Article

M3 - Tidsskriftartikel

C2 - 26815584

SN - 0041-5782

VL - 178

SP - 2

EP - 6

JO - Ugeskrift for Laeger

JF - Ugeskrift for Laeger

IS - 3

ER -

Immunterapi mod Alzheimers sygdom

Abstract

Keywords

Fingerprint

Cite this